Pro-Dex, Inc., together with its subsidiaries, designs, develops, and manufactures powered surgical instruments, dental instruments, and rotary air motors worldwide. It also manufactures plastic injection molds for various industries; and shavers and machined parts. In addition, it provides engineering, and quality and regulatory consulting services. The company offers its products under the name of Pro-Dex.Pro-Dex, Inc. sells its medical device products primarily to original equipment manufacturers; and dental products to dental product distributors. Its products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone949-769-3200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$27.17 million
Profitability
Miscellaneous
Employees80
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable
Pro-Dex (NASDAQ:PDEX) Frequently Asked Questions
What is Pro-Dex's stock symbol?
Pro-Dex trades on the NASDAQ under the ticker symbol "PDEX."
How were Pro-Dex's earnings last quarter?
Pro-Dex Inc (NASDAQ:PDEX) posted its earnings results on Thursday, August, 30th. The medical instruments supplier reported $0.22 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.06 by $0.16. Pro-Dex had a return on equity of 24.02% and a net margin of 15.32%. View Pro-Dex's Earnings History.
When is Pro-Dex's next earnings date?
What price target have analysts set for PDEX?
1 analysts have issued 12 month target prices for Pro-Dex's shares. Their predictions range from $20.00 to $20.00. On average, they anticipate Pro-Dex's share price to reach $20.00 in the next year. This suggests a possible upside of 47.3% from the stock's current price. View Analyst Price Targets for Pro-Dex.
What is the consensus analysts' recommendation for Pro-Dex?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pro-Dex in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pro-Dex.
Has Pro-Dex been receiving favorable news coverage?
News stories about PDEX stock have been trending negative on Thursday, InfoTrie reports. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Pro-Dex earned a news sentiment score of -2.3 on InfoTrie's scale. They also gave news articles about the medical instruments supplier a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Pro-Dex.
Are investors shorting Pro-Dex?
Pro-Dex saw a decline in short interest during the month of September. As of September 30th, there was short interest totalling 11,000 shares, a decline of 5.2% from the August 30th total of 11,600 shares. Based on an average trading volume of 14,600 shares, the days-to-cover ratio is presently 0.8 days. Currently, 0.4% of the company's shares are sold short. View Pro-Dex's Current Options Chain.
Who are some of Pro-Dex's key competitors?
Some companies that are related to Pro-Dex include Soliton (SOLY), SeaSpine (SPNE), Vapotherm (VAPO), Neuronetics (STIM), Repro-Med Systems (REPR), Cytosorbents (CTSO), RenovaCare (RCAR), iCAD (ICAD), T2 Biosystems (TTOO), BRAINSWAY LTD/S (BWAY), Sensus Healthcare (SRTS), Liquidia Technologies (LQDA), Spectral Medical (EDTXF), Nephros (NEPH) and Endologix (ELGX).
What other stocks do shareholders of Pro-Dex own?
Who are Pro-Dex's key executives?
Pro-Dex's management team includes the folowing people:
- Mr. Richard Lee Van Kirk Jr., CEO, Pres, COO & Director (Age 58)
- Mrs. Alisha K. Charlton, CFO & Corp. Sec. (Age 49)
How do I buy shares of Pro-Dex?
Shares of PDEX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Pro-Dex's stock price today?
One share of PDEX stock can currently be purchased for approximately $13.58.
How big of a company is Pro-Dex?
What is Pro-Dex's official website?
How can I contact Pro-Dex?
Pro-Dex's mailing address is 2361 MCGAW AVENUE, IRVINE CA, 92614. The medical instruments supplier can be reached via phone at 949-769-3200 or via email at [email protected]
MarketBeat Community Rating for Pro-Dex (NASDAQ PDEX)
MarketBeat's community ratings are surveys of what our community members think about Pro-Dex and other stocks. Vote "Outperform" if you believe PDEX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PDEX will underperform the S&P 500 over the long term. You may vote once every thirty days.
